Pointe Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Pointe Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-89,523	Closed	-$204K	–	149
2016 Q2	$204K	Hold	89,523	–	–	0.15%	142
2016 Q1	$225K	Sell	89,523 -7,520	-8%	-$16.8K	0.18%	126
2015 Q4	$321K	Hold	97,043	–	–	0.23%	116
2015 Q3	$235K	Hold	97,043	–	–	0.14%	145
2015 Q2	$284K	Hold	97,043	–	–	0.13%	143
2015 Q1	$389K	Buy	+97,043	New	+$336K	0.18%	102

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pointe Capital Management's LCTX Position: Q3 2016 in Review

Pointe Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q3 2016, closing a stake of 89,523 shares — an estimated $204K sold.

Pointe Capital Management first reported a position in LCTX in Q1 2015 and held it in 6 quarters. The position peaked at $389K in Q1 2015. 80 funds tracked by Wall St. Rank hold LCTX as of Q3 2016.

Pointe Capital Management reported no remaining Lineage Cell Therapeutics position as of Q3 2016 after selling out during the quarter.
Pointe Capital Management sold 89,523 Lineage Cell Therapeutics shares in Q3 2016, an estimated $204K.
Pointe Capital Management first reported a position in Lineage Cell Therapeutics in Q1 2015 and held it in 6 quarters.
Pointe Capital Management's Lineage Cell Therapeutics position peaked at $389K in Q1 2015.
80 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2016.

Based on Pointe Capital Management's 13F filing for Q3 2016, filed 2 Nov 2016.